January 24, 2023 07:29 AM ESTUpdated 03:58 PM
Financing

Fol­low­ing pos­i­tive da­ta for pul­monary fi­bro­sis drug, Pli­ant to sell $175M in stock

Katherine Lewin

News Reporter

A day af­ter Pli­ant Ther­a­peu­tics shared pos­i­tive tri­al da­ta for its pul­monary fi­bro­sis drug that sent its stock up 50%, the com­pa­ny plans to sell …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times